Cardiac safety of gamithromycin in ewes

Orhan Çorum1,2, Burak Dik1, Emre Bahçivan1,3, Hatice Eser1,2, Ayşe Er1*, Enver Yazar1

1Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Selcuk, Konya, 2Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Dicle, Diyarbakir, 3Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Kafkas, Kars, Turkey

Received: 28.03.2016, Accepted: 09.05.2016

*ayer@selcuk.edu.tr

Koyunlarda gamitromisinin kardiak güvenilirliği

Öz


Gereç ve Yöntem: Araştırmada 10 adet koyuna gamithromisin (6 mg/kg, SC) tek doz olarak uygulandı. Kan örnekleri uygulamadan önce (0. gün, kontrol) ve sonraki 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8 ve 9. günlerde alındı. Spesifik kalp hasar belirteçleri olan serum kreatin kinaz-MB kütle ve troponin I düzeyleri, karaciğer ve böbrek hasar belirteçleri ve hemogram parametrelerine ölçüldü.

Bulgular: Araştırmada troponin I düzeyinde birinci gün istatistik olmayan yükselmele roruk etiketlenmedi. Total bilirubin, total protein, kreatinin ve akyüvar düzeyinde referans değerler arasında istatistikte değişilmez belirlendi (P<0.05).

Öneri: Koyunlara tek doz gamitromisin (6 mg/kg, SC) uygulamasının kalp, karaciğer, böbrek fonksiyonları ile hemogram parametrelerine belirgin yan etkilerinin olmadığı ifade edilebilir.

Anahtar kelimeler: Koyun, gamitromisin, güvenilirlik

Abstract

Aim: Gamithromycin, a macrolide antibiotic, is used in the treatment of bovine pasteurellosis, whereas it is used in sheep as extra-label. It is well known that macrolide antibiotics have cardiotoxic effect, however, it cannot be found the information of cardiac safety of gamithromycin in sheep in the literature. The first aim of this research was to determine the cardiac safety of gamithromycin in sheep. In addition, effects of gamithromycin on the liver and kidney functions and hemogram values were investigated.

Materials and Methods: Gamithromycin (6 mg/kg, SC) was administered as a single dose to 10 sheep. Blood samples were taken before (0. day, control) and after treatments at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8 and 9 days. Serum creatine kinase-MB mass and troponin I levels which are specific cardiac damage markers, liver, kidney damage markers and hemogram values were measured.

Results: Increased troponin I levels were determined at first day but it was not statistically significant, and there was no change determined in the creatine kinase-MB mass levels. Statistically significant (P<0.05) fluctuations were determined in the total bilirubin, total protein, creatinine and white blood cell counts, but these results were within the normal ranges.

Conclusion: It may be stated that single dose (6 mg/kg, SC) gamithromycin administration has no distinctive side effects on the heart, liver and kidney functions and hemogram values in sheep.

Keywords: Sheep, gamithromycin, safety
Introduction

Semi-synthetic antibiotic gamithromycin belongs to azalide subclass of macrolide antibiotics and it comprises of a 15-membered macrocyclic lactone ring. Gamithromycin has been developed for only veterinary medicine and is recommended at 6 mg/kg (SC) single dose in the prevention and/or treatment of Mannheimia haemolytica, Pasteurella multocida and Histophilus somni caused bovine respiratory disease in non-lactating dairy cattle. Macrolides show their antibacterial activity via inhibiting of protein biosynthesis. In the cattle, after 6 mg/kg (SC) injection, gamithromycin has long plasma elimination half-life (50 hours), large apparent volume of distribution (25 L/kg), higher bioavailability (~100%), quick and widespread distribution to lung tissue and prolonged lung tissue half-life. These characteristic pharmacokinetic values of gamithromycin are beneficial in the treatment of lung infections in cattle (EMEA 2009, Huang et al 2009, Baggott et al 2011). In the studies, it has been reported that administration of gamithromycin prior to Mannheimia haemolytica serotype A1 challenged calves has reduced the bacterial isolation from the lungs and severity of clinical signs of disease (Forbes et al 2011), and it has antimycoplasmal effect against to Mycoplasma bovis in non-lactating dairy cattle (Lechtenberg et al 2011).

Although gamithromycin was approved in the treatment of bovine respiratory disease in non-lactating dairy cattle by European Medicines Agency (EMEA 2009), drug may be used or suggested as extra-label in sheep (Strobel et al 2014), pigeons (Wyns et al 2014), foals (Berghaus et al 2012) and broiler chicks (Watteyn et al 2013). According to pharmacokinetic research, single dose (6 mg/kg, SC) gamithromycin has been recommended in the sheep, and gamithromycin is suggested in the therapy of foot-rot in sheep (Kellermann et al 2014, Strobel et al 2014). Although gamithromycin may be used as extra-label in animals except for cattle, no detailed safety information is present, and commonly observed side effects of macrolide antibiotics are cardiotoxicity and hepatotoxicity (Andrade and Tulkens 2011, Yazar 2012).

Materials and Methods

Study protocol was approved by Ethic Committee of Veterinary Faculty, Selcuk University. Gamithromycin (Zactran® enj., Sanofi, Turkey) was administered as a single dose at 6 mg/kg subcutaneously to 10 Afdakaman sheep (>1 years 52.10±1.66 kg). Blood samples were taken before (Control, day 0) and after treatments at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8 and 9 days. Specific cardiac damage markers (Troponin I and CK-MB mass) were measured by Siemens AdviaCentaur XP (Erlangen, Germany). Hepatic (ALP, total bilirubin, ALT, AST, GGT, total protein) and renal (BUN, creatinine) damage markers were determined by auto-analyzer (ILab-300 plus, Instrumentation Laboratory, Milano, Italy), while hemogram values (WBC, RBC, platelet, hematocrit) were determined by hemocell counter (BC-2800 Auto Hematology Analyzer, Mindray Bio-Medical Electronics, Shenzen, China).

Study results were presented mean ± SE. Data were evaluated ANOVA and Scheffe as posthoc test. P<0.05 level was accepted statistically significant.

Results

Effect of gamithromycin on troponin I and CK-MB mass concentrations are shown in Graphic 1 and 2, respectively. Troponin I reached peak levels at first days after gamithromycin administration, but this difference was not statistically significant (P>0.05) within the days. There were any changes in the CK-MB mass levels, as well (P>0.05). Statistically significant fluctuations were determined (P<0.05) in the total bilirubin, total protein, creatinine and WBC levels, whereas no statistically significance were observed (P>0.05) in the other biochemical and hematological values (data not shown).
Discussion

Gamithromycin is used or recommended in some infections of sheep as extra-label drug (Kellermann et al. 2014, Strobel et al. 2014), although it has been recommended by the European Medicines Agency in the treatment of bovine respiratory disease caused by Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in non-lactating dairy cattle (EMEA 2009).

In the current research, after gamithromycin administration, peak level of troponin I was determined at first day (24th hours), but this result was not statistically significant (P>0.05, Graphic 1), and there was no statistically significant changes determined (P>0.05) in the CK-MB mass levels (Graphic 2). Blood CK-MB and troponin I levels are evaluated in the diagnosis of cardiac damage. Higher CK-MB and troponin I concentrations are detected within first 4 – 6 hours after myocardial infarction (Harrison and Amundson 2005, O'Brien 2008, Hallen 2012). Increased CK-MB mass and troponin I concentrations are used in the described of cardiac damage in sheep like humans (Ekici and Isik 2011, Er et al. 2013). Cardiotoxic side effects of macrolide antibiotics are well known (Yazar et al 2001, Yazar 2012). Tilmicosin, a macrolide antibiotic, may cause death in lamb (Dogan 2011) and increases CK-MB and troponin I levels in rabbits (Yazar et al 2002). In addition, tulathromycin may increase CK-MB and troponin I levels in rabbits (Er et al. 2011) and sheep (Corum et al. 2015). When current research results related with cardiac damage markers are evaluated, it may be stated that gamithromycin has no distinctive cardiotoxic effect, though it has increased troponin I levels in sheep.

In the present study, gamithromycin caused statistically significant (P<0.05) fluctuations in total bilirubin, total protein, creatinine and WBC levels. However, these results are within normal range reported about healthy sheep (Bulbul 2013, Corum et al. 2015, Er et al. 2015).

Conclusion

It may be stated that administration of single dose gamithromycin (6 mg/kg, SC) do not cause cardiac damage, and it has no side effects on the liver and kidney functions and hemogram values in sheep. However, histopathological evaluations should be done to fully determination of gamithromycin safety in sheep.

Acknowledgements

Study was financed by SUBAPK (15401150). Study abstract was presented as poster in 7th European Congress of Pharmacology in 26-30 June 2016, Military Museum and Cultural Center, Istanbul, Turkey, and pressed proceeding book.

References

Er A, Corum O, Dik B, Bahcivan E, Eser H, Yazar E, 2015. De-


Hallen J, 2012. Troponin for the estimation of infarct size: what have we learned?. Cardiology, 121, 204-212.


O’Brien PJ, 2008. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardotoxicity. Toxicology, 245, 206-218.


